Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
R413678-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $162.90 | |
R413678-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $489.90 |
SMN Modulators
Synonyms | RG7916;RO7034067 | RG7916 | RG-7916 | RO7034067 | RO-7034067 | 2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-(4,7-diazaspiro[2.5]octan-7-yl)-4H-pyrido[1,2-a]pyrimidin-4-one | AMY23728 | AKOS040742554 | Evrysdi | Risdiplam | RISDIPLAM [ORANGE BOOK] | Risd |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Biochemical and Physiological Mechanisms | Risdiplam (Evrysdi, RG7916, RO7034067) is an orally administered SMN2 pre-mRNA splicing modifier that distributes into the central nervous system (CNS) and peripheral tissues. |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Product Description | Information Risdiplam (RG7916) Risdiplam (Evrysdi, RG7916, RO7034067) is an orally administered SMN2 pre-mRNA splicing modifier that distributes into the central nervous system (CNS) and peripheral tissues. Targets SMN2 |
ALogP | 0.5 |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one |
---|---|
INCHI | InChI=1S/C22H23N7O/c1-14-9-18(26-29-11-15(2)24-21(14)29)17-10-20(30)28-12-16(3-4-19(28)25-17)27-8-7-23-22(13-27)5-6-22/h3-4,9-12,23H,5-8,13H2,1-2H3 |
InChi Key | ASKZRYGFUPSJPN-UHFFFAOYSA-N |
Canonical SMILES | CC1=CC(=NN2C1=NC(=C2)C)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(C5)CC6 |
Isomeric SMILES | CC1=CC(=NN2C1=NC(=C2)C)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(C5)CC6 |
Alternate CAS | 1825352-65-5 |
PubChem CID | 118513932 |
MeSH Entry Terms | 7-(4,7-Diazaspiro(2.5)oct-7-yl)-2-(2,8-dimethylimidazo(1,2-b)pyridazin-6-yl)-4H-pyrido(1,2-a)pyrimidin-4-one;Risdiplam |
Molecular Weight | 401.46 |
Enter Lot Number to search for COA:
Solubility | Solubility (25°C) In vitro DMSO: Insoluble; Water: Insoluble; Ethanol: Insoluble; |
---|
Pictogram(s) | GHS07 |
---|---|
Signal | Warning |
Hazard Statements | H302:Harmful if swallowed |
Precautionary Statements | P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P270:Do not eat, drink or smoke when using this product. P330:Rinse mouth. P301+P317:IF SWALLOWED: Get medical help. |
1. Ratni H, Ebeling M, Baird J, Bendels S, Bylund J, Chen KS, Denk N, Feng Z, Green L, Guerard M et al.. (2018) Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA).. J Med Chem, 61 (15): (6501-6517). [PMID:30044619] [10.1021/op500134e] |
2. Poirier A, Weetall M, Heinig K, Bucheli F, Schoenlein K, Alsenz J, Bassett S, Ullah M, Senn C, Ratni H et al.. (2018) Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs.. Pharmacol Res Perspect, 6 (6): (e00447). [PMID:30519476] [10.1021/op500134e] |
3. Kletzl H, Marquet A, Günther A, Tang W, Heuberger J, Groeneveld GJ, Birkhoff W, Mercuri E, Lochmüller H, Wood C et al.. (2019) The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy.. Neuromuscul Disord, 29 (1): (21-29). [PMID:30553700] [10.1021/op500134e] |